🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to share our latest work in Journal for ImmunoTherapy of Cancer! David Faleck Steve Maron Darren Cowzer Yelena Y. Janjigian MD Memorial Sloan Kettering Cancer Center MSK Department of Medicine

Let’s look closer at “Impact of Helicobacter Pylori Infection Status on Outcomes among Patients with Advanced Gastric Cancer Treated with Immune Checkpoint Inhibitors” by Monika Laszkowska, MD, MS David Faleck Steve Maron & Yelena Y. Janjigian MD from Memorial Sloan Kettering Cancer Center, recently in #JITC. 1/9

Thank you Journal for ImmunoTherapy of Cancer for highlighting our work and my excitement about all things GI + microbiome + cancer + immunotherapy! Grateful for fantastic collaborators Memorial Sloan Kettering Cancer Center including Monika Laszkowska, MD, MS Steve Maron Yelena Y. Janjigian MD and many others

Very grateful for my phenomenal and incredibly dedicated #colitis team Memorial Sloan Kettering Cancer Center and honored to receive the Dept of Medicine team-based award for "Excellence in Outpatient Care Collaboration". Truly takes a team to manage these complex patients. #IBD #irColitis

Excited to share our study on the dysbiosis associated with #checkpointcolitis and ability to treat with #FMT. Fantastic collaboration with @ArielleElkrief and Jonathan (Tsoni) Peled who led the microbiome work. More to come in this space... Memorial Sloan Kettering Cancer Center pubmed.ncbi.nlm.nih.gov/38108398/?s=09

New #JITC article: Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series bit.ly/3Umnd23 Catriona Harvey Serigne Lo @McQuadeMDLAc Matteo Carlino Professor Georgina Long AO (Bluesky @gvlongphdmd) Christian Blank

Join us for a vital update on advancements in diagnosing, treating, & monitoring #GI premalignant & malignant conditions. Don't miss out on expert-led discussions covering Barrett's esophagus, hepatocellular carcainoma, & more #MSKgastroCME Register at bit.ly/MSKGI2024

Join us June 20 for the Oncologic Toxicity Management Symposium #MSKOTMCME. Expert faculty will present a cutting-edge, multidisciplinary approach to managing adverse events from modern oncology treatments. Learn more about this exciting program: bit.ly/OTMsymposium

Outstanding work Tanisha Kalra, MD expanding our knowledge of #immunotherapycolitis, in particular the underappreciated long duration of symptoms (>12 weeks) in many of our patients Memorial Sloan Kettering Cancer Center Keep up the good work!

Thank you Dr Neil Shah Memorial Sloan Kettering Cancer Center for the keynote invite to the #MSKOTMCME —impressive multidisciplinary science-driven approach to immune-related toxicities! Sasha Gusev Maxine Sun Eddy Saad Dana-Farber Dana-Farber Lank Center for Genitourinary Oncology

Happy to share our experience using open capsule budesonide for successful treatment of immune-related enteritis. Grateful for my fantastic team Memorial Sloan Kettering Cancer Center who help treat these pts and made this study possible and ⭐️ med student Patrick Magahis for putting this together.

Here’s a closer look at recent #JITC article “Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors” by Patrick Magahis & David Faleck from Weill Cornell Medicine & Memorial Sloan Kettering Cancer Center. 1/11

In Journal of Experimental Medicine, Joan Shang, David Faleck, Jeremiah Faith et al. report that pretreatment gut #microbiomes of #immunotherapy-related colitis patients drive worse #colitis in susceptible mice compared with non-colitis cancer immunotherapy microbiomes. hubs.la/Q02_rp9_0

Does the gut #microbiome predispose patients to immunotherapy-related colitis? Our study in Journal of Experimental Medicine explores the #microbiota before, during, and after #colitis induced by #cancer #immunotherapy in a prospective cohort. Read here: hubs.la/Q02_r1nl0 #MedTwitter #GITwitter

Patients with #IBD and a history of cancer who have been treated with various immunosuppressive medications were found to have no greater risk of developing recurrent or new cancers compared to patients with IBD who were not exposed to these medications: ow.ly/2qZV50VmpQi

At the 🔀of oncology & IBD: Let’s talk immunotherapy-induced enterocolitis (ICI/IMC) 📌#Back2Basics April14 📌Convo David Faleck April28 🆓#CME 👉🏽bit.ly/MNIBD24-25 🗳️PreB2B polls👇🏽 Support by educ grant AbbVie JanssenUS Takeda 📍Where are you in your 🩺

At the 🔀of oncology & IBD: Let’s talk #immunotherapy in pts w #IBD 📌Convo David Faleck April 28 (Check the🌟B2B🧵on ICI-colitis👇🏽) 🆓#CME 👉🏽bit.ly/MNIBD24-25 🗳️PreConvo CME polls👇🏽 Support by educ grant AbbVie JanssenUS Takeda 📍Where are you in your 🩺

#MondayNightIBD Aline Charabaty, MD, FACG, AGAF 55M w/ UC x30y. Prior 5-ASA, 6MP. On IFX 5 mg/kg q8w x5y. Mild UC sx before infusions. 🔦Last scope 1y ago: Mayo 0. Now FCP 141, IFX level 3. New dx: metastatic melanoma → onc is starting nivolumab. What do you recommend for his UC?

Congrats to our star med student / soon to be IM resident Patrick Magahis and our team Memorial Sloan Kettering Cancer Center on this important study of CDI rates and outcomes in >600 pts on cancer immunotherapy

Novel therapies are revolutionizing the landscape of cancer treatment. Join us in two weeks for a critical forum to explore the evolving landscape of cancer therapeutics, their clinical applications, & evidence-based strategies to mitigate treatment-related toxicities: